Table 2. Clinicopathological features of breast cancer with or without Wnt antagonist genes methylation.
|
SFRP1
|
SFRP2
|
SFRP5
|
DKK1
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | U | M | P-value | U | M | P-value | U | M | P-value | U | M | P-value | |
| Total | 78 | 47 | 31 | 18 | 60 | 23 | 55 | 63 | 15 | ||||
| Age (years, mean±s.d.) | 53.66±11.01 | 52.22±11.97 | 53.56±12.03 | 52.95±11.24 | 52.78±8.88 | 53.22±12.31 | 52.46±11.43 | 55.73±10.96 | |||||
| pT category | |||||||||||||
| pTis | 1 | 0 | 1 | 0.796 | 0 | 1 | 0.629 | 0 | 1 | 0.860 | 1 | 0 | 0.129 |
| pT1 | 17 | 12 | 5 | 4 | 13 | 6 | 11 | 13 | 4 | ||||
| pT2 | 41 | 25 | 16 | 11 | 30 | 10 | 31 | 32 | 9 | ||||
| pT3 | 8 | 4 | 4 | 1 | 7 | 5 | 3 | 8 | 0 | ||||
| pT4 | 7 | 5 | 2 | 1 | 6 | 1 | 6 | 7 | 0 | ||||
| pN category | |||||||||||||
| pN0 | 35 | 20 | 15 | 0.809 | 9 | 26 | 0.678 | 7 | 28 | 0.125 | 29 | 6 | 0.747 |
| pN1 | 28 | 20 | 8 | 6 | 22 | 11 | 17 | 21 | 7 | ||||
| pN2 | 6 | 2 | 4 | 2 | 4 | 1 | 5 | 6 | 0 | ||||
| pN3 | 3 | 2 | 1 | 0 | 3 | 2 | 1 | 3 | 0 | ||||
| pM category | |||||||||||||
| pM0 | 66 | 40 | 26 | 1.000 | 17 | 49 | 0.325 | 20 | 46 | 0.664 | 53 | 13 | 0.583 |
| pM1 | 6 | 4 | 2 | 0 | 6 | 1 | 5 | 6 | 0 | ||||
| ER | |||||||||||||
| Negative | 15 | 10 | 5 | 0.517 | 6 | 9 | 0.292 | 6 | 9 | 0.128 | 14 | 1 | 0.286 |
| Positive | 26 | 13 | 13 | 5 | 21 | 4 | 22 | 19 | 7 | ||||
| HER2 | |||||||||||||
| Negative | 24 | 15 | 9 | 0.353 | 9 | 15 | 0.086 | 5 | 19 | 0.714 | 19 | 5 | 0.714 |
| Positive | 18 | 8 | 10 | 2 | 16 | 5 | 13 | 15 | 3 | ||||
| Histology | |||||||||||||
| Ductal carcinoma in situ | 4 | 3 | 1 | 2 | 2 | 1 | 3 | 4 | 0 | ||||
| Invasive ductal carcinoma | 63 | 37 | 26 | 11 | 52 | 18 | 45 | 51 | 12 | ||||
| Lobular carcinoma in situ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Invasive lobular carcinoma | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | ||||
| Others | 7 | 6 | 1 | 4 | 3 | 3 | 4 | 5 | 2 | ||||
ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2.